Peptide–Drug Conjugates: Synthesis and Applications
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Applied Chemistry".
Deadline for manuscript submissions: 28 February 2025 | Viewed by 31
Special Issue Editor
Interests: drug development; theranostics; diagnostics; therapeutics; plant extracts
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
There is currently a very active revival of interest in the exploitation of peptides as core tools to develop novel drugs, diagnostics, and theranostics for creating new high value-added products to address unmet medical needs. This emanates from their biocompatibility, enhanced biochemical characteristics with respect to targeted delivery, and ease in rational design and production. In particular, peptide–drug conjugates (PDCs) are arguably an inextricable accessory in our armamentarium against cancer and are continuously gaining attention as a viable approach for selectively targeting malignant cells. Moreover, the conjugation of a bioimaging agent, a drug, or a combination of both modalities to a peptide that targets a specific biomarker expressed in a diseased location in a tissue can generate a potent diagnostic, therapeutic, or theranostic agent. This Special Issue will collect recent advances and developments in the field of peptide–drug conjugates (PDCs), imaging (diagnostic), or dual modalities (theranostics) against cancer and other diseases, including the rational design of and novel methodologies for the synthesis (e.g., rapid click chemistry reactions) of novel peptide conjugates. The contributions will also be focused on the impact of the linker in the overall pharmaceutical profiles of peptide conjugates, the interactions with the targeted biomarker, the discovery of novel targets, and the possible side-product formation that may occur during such conjugations.
PDCs consist of three building blocks: the tumor-targeting peptide, the cytotoxic drug, and the biodegradable tether (linker). This Special Issue will collect recent advances in the field of peptide–drug conjugates against cancer, including the rational design of novel peptide–drug conjugates and novel methodologies for their synthesis (e.g., the development of rapid click reactions). The contributions will also be focused on the impact of the linker on the overall pharmaceutical profiles of PDCs, the receptor-binding interactions, the discovery of novel molecular targets, and the possible side-product formation that may occur during such conjugations.
Dr. Andreas Tzakos
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- peptide–drug conjugates
- peptide-based diagnostics
- peptide-based theranostics
- rational design
- cancer research
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
